• Special Issue Topic

    Emerging Nanomedicine Technologies for Enhanced Cancer Theranostics

    Submission Deadline: November 30, 2024

    Guest Editor

    Prof. Xiangyang Shi E-Mail

    Professor of Biomedical Engineering, College of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai, China

    Research Keywords: dendrimers; polymer nanogels; cancer nanomedicine; drug/gene delivery; theranostics


    About the Special Issue

    Cancer theranostics have been demonstrated as the advanced platforms that can diagnose cancer at early stages and initiate subsequent therapy to impove the survival rate of patients. With the development of nanotechnologies, multifunctional nanoplatforms have shown a good application prospect in enhanced cancer theranostics. Through the ingenious design of nanoplatforms, various imaging and therapeutic agents can be physically loaded or chemically conjugated onto the platforms to optimally exert their functionalities of theranostics. Nanomedicines are contimuously seeking contribution from the therapeutic and diagnostic agents at the nanoscale through creative leveraging of their mechanical, electrical, optical, magnetic, and biological properties. This special issue entitled “Emerging nanomedicine technologies for enhanced cancer theranostics” brings together some of the world's foremost experts to discuss the current key developments in the area of emerging nanomedicine technologies in cancer nanotheranotics, including but not limited to strategic design of nanomedicines to tackcle multi-drug resistance, tumor targeting delivery, modulation of tumor microenvironment, combination therapy, precision imaging, inhibition of cancer metastasis and recurrence, and modulation of immune cells. 

    Keywords: drug delivery systems; gene delivery; molecular imaging; cancer theranostics; tumor microenvironment

    Call for Papers

    Published Articles

    Open Access
    Review
    Effect of the size of nucleic acid delivery systems on their fate in cancer treatment
    Nucleic acid therapeutics are emerging as a promising class of medicines, offering unique therapeutic options for cancer at the gene level. However, the druggability of nucleic acid therapeutics is  [...] Read more.
    Mengyun Ye ... Dandan Zhu
    Published: February 01, 2024 Explor Drug Sci. 2024;2:38–49
    DOI: https://doi.org/10.37349/eds.2024.00035
    View:807
    Download:23
    Times Cited: 0
    Open Access
    Review
    Electrospun short fibers: a new platform for cancer nanomedicine applications
    With the continuous development of nanomaterials, nanofibers prepared by electrospinning have gradually occupied people’s vision because of their unique advantages, such as crisscross network and  [...] Read more.
    Yifan Huang ... Xiangyang Shi
    Published: December 27, 2023 Explor Drug Sci. 2023;1:454–467
    DOI: https://doi.org/10.37349/eds.2023.00030
    View:1009
    Download:32
    Open Access
    Review
    Nano theranostics involved in bladder cancer treatment
    Bladder cancer (BC) is a complex disease with multiple clinical manifestations and treatment challenges, and current standard-of-care therapies remain limited and unfavorable. Theranostics, the inte [...] Read more.
    Kunpeng Liu ... Qingsong Yu
    Published: April 28, 2023 Explor Drug Sci. 2023;1:81–106
    DOI: https://doi.org/10.37349/eds.2023.00008
    View:1821
    Download:45
    Times Cited: 0
    Open Access
    Original Article
    Surface functionalized mesoporous polydopamine nanocomposites for killing tumor cells through collaborative chemo/photothermal/chemodynamic treatment
    Aim: The development of a collaborative strategy with improved efficacy holds great promise in tumor treatment. This study aims to develop an effective collaborative strategy based on functionalized mesoporous polydopamine (MPDA)  [...] Read more.
    Yi Ouyang ... Hui Liu
    Published: February 27, 2023 Explor Drug Sci. 2023;1:18–30
    DOI: https://doi.org/10.37349/eds.2023.00003
    View:2384
    Download:113
    Times Cited: 0